Stockreport

Tiziana Reports Promising Data Showing Nasal Anti-CD3 May Improve Age-Related Cognitive Decline [TheStreet.com]

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF Tiziana Life Sciences (Nasdaq: TLSA) has released new preclinical data demonstrating that its intranasal anti-CD3 therapy , foralumab, may help reverse key aspects of b [Read more]